Breast CancerPhase 2/3NCT03564171
Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer
A Phase 2/3 study testing Prehabilitation in people with Breast Cancer and Rehabilitation, run by Sunnybrook Health Sciences Centre at 1 site in Canada.
Trial summary
To assess recruitment rate, attrition, compliance with weekly exercise, smoking cessation, and quality of life with a multimodal prehabilitation protocol for women with breast cancer undergoing neo-adjuvant chemotherapy for breast cancer. Read more about this study
- Who is it for?
- Ages 18 to 80 years, women only
- Conditions the study is for
- Breast Cancer, Rehabilitation, Neoadjuvant Therapy
- What is being tested?
- Prehabilitation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 63 participants
- Where
- 1 siteCanada
- Study dates
- 18 Jul 2018to 31 Mar 2023
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years and older, able to give consent, ECOG 0-1
Who cannot join
- pregnant, > 80 years, medical contraindications to exercise. History of severe and persistent mental illness, cognitive impairment, recent suicide attempts or >11 on "Hospital Anxiety and Depression Scale". If very active (> 24) on the Godin-Shephard scale.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized Controlled Feasibility Study Comparing a Multimodal Prehabilitation Protocol to Normal Care for Women Undergoing Neo-adjuvant Chemotherapy for Breast Cancer
To assess recruitment rate, attrition, compliance with weekly exercise, smoking cessation, and quality of life with a multimodal prehabilitation protocol for women with breast cancer undergoing neo-adjuvant chemotherapy for breast cancer.
Read the detailed description
Proposal: A randomized controlled feasibility study comparing a multi-modal prehabilitation protocol to usual care for women undergoing neo-adjuvant therapy for breast cancer.
Methods: Study population: Sixty patients who are undergoing curative intent neo-adjuvant chemotherapy for breast cancer will be randomized to intervention (n=30) or standard care (n=30) at a single site (Sunnybrook).
Intervention: A multi-modal program composed of an exercise prescription that will progressively increase in intensity and duration towards the current physical activity guidelines, nutritional counseling, stress counseling, and smoking cessation (as needed).
Intervention: Exercises will be instructed and demonstrated by a physiotherapist prior to the initiation of chemotherapy and will continue up until surgery. Nutritional and stress counseling, as well as smoking cessation, will be offered at initial consult with physiotherapist.
Exercise Protocol: The prehabilitation program entails a home-based exercise with both total-body physical exercise and exercises specific to the upper quadrant over the period between baseline assessment and surgery. The exercise prescription will be provided by a physiotherapist based upon the baseline assessment and will consist of a goal of 60 minutes of home-based, unsupervised exercise on 4 days per week, including aerobic and resistance training. Each session will be individualized and based upon the baseline assessment and generally include: a 5-minute warm-up, 25 minutes of moderate intensity aerobic exercise (for example: brisk walking, treadmill, stationary bike) (intensity of 3-6 on the 0-10 Rating of Perceived Exertion Scale) (attached, Appendix A) and 25 minutes of upper quadrant-specific training (Appendix B), and a 5-minute cool-down consisting of stretches (Appendix B). The program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. The participant will have an opportunity to try the exercises in the presence of the physiotherapist who will provide corrective feedback if necessary. The physiotherapist will discuss safety precautions (posture, breathing, etc.) and provide the participant with an exercise manual that describes the exercises in the program and the safety precautions. To complete the exercises at home, each participant will be provided with resistance Theraband(s) (red and yellow) required to complete the upper quadrant exercises that they may keep at the end of the study. Training intensity progression will occur when the participant can complete the aerobic exercise with mild exertion and/or when the participant can complete 15 repetitions of a given upper quadrant exercise without eliciting at least moderate exertion (i.e. 3 to 6 on the Rating of Perceived Exertion scale). The prehabilitation program will be supported with a manual including institutionally created postoperative rehabilitation exercises that comprise a significant proportion of the preoperative exercise prescription. The physiotherapist will communicate with the participants every 2 weeks to ensure program compliance, support appropriate progression, and to address any barriers to exercise (including questions about appropriate exercise completion) that may prevent ongoing participation (see contact with team Table 1).
Grip Strength: Grip strength is commonly used to assess upper extremity strength in patients with breast cancer (Sagen 2009) and will be assessed via the "Jamar Hand" dynamometer according to established protocols.
Aerobic Fitness: Aerobic fitness will be measured using the 6-minute walk test (6 Minute Walk Test). This test is a practical standardized measure of functional capacity and has been widely used for measuring the submaximal level of functional capacity in cancer patients (Vardar 2015, Santa Mina 2014, Schmidt 2013). This test will measure the distance that the patient can walk on a flat, hard surface in a period of 6 minutes.
Nutrition counseling: The registered dietitian will provide an initial individualized nutrition assessment and counseling session. The consultation will be about 60 minutes in length and can be conducted in person or via telephone.
The patient's nutritional history, assessment of usual intake and weight history will be reviewed to help identify any nutritional issues/concerns. The session will focus on the goals of nutrition before and during treatment, provide strategies to help the patient optimize or enhance the nutritional quality of the diet, maintain a healthy weight and minimize weight gain and address any nutrition-related questions or concerns.
The registered dietitian will follow-up with the patient 4 weeks after the initial consultation to review the nutrition care goals and outcomes, answer questions re. any potential nutrition-related side effects from treatment and address any other questions or concerns.
The patient will be encouraged to contact the dietitian as needed during treatment for on-going support of if any nutrition related questions or concerns.
Stress counseling: Stress management intervention: Stress management intervention will consist of a 60-90 minute individual session with a psychiatrist specializing in psychosocial oncology. The therapy session will be cognitive-behavioral in orientation. The components will include a psychoeducational module on the stress response to physical symptoms; problem-solving and coping skills; relaxation techniques; and guided imagery. During the initial session, participants will be oriented conceptually to four types of interventions for reducing anxiety and coping with stress: (1) Progressive muscle relaxation; (2) mindfulness; (3) deep breathing; and (4) imagery/visualization. Each intervention will have accompanying written materials, which will also contain links to online audio materials. The additional materials contain written and spoken instructions allowing for self-directed learning and practice of each of the four stress-reducing interventions. Participants will be invited to choose one or two of the four strategies to practice with the therapist in the initial session, and in any subsequent sessions that participants attend. The therapist will instruct participants to choose one audio file to listen to at each chemotherapy session.
Optional face-to-face 60 minute individual booster sessions will be offered to participants on a monthly basis until surgery, in order to review problem solving and coping skills, relaxation techniques, and guided imagery. If patients are found to need a greater frequency of psychiatric intervention or undergo a psychiatric crisis, or if they require psychotropic medications at any point during the study, the PI will be informed and a referral will be made to an alternate psychiatrist (if the patient chooses) at the Odette Cancer Centre who is not involved in this study.
Every 2 weeks the patients in the intervention (prehabilitation arm) will be asked these questions:
At each telephone follow-up or email, the frequency of use and acceptability will be assessed with the following questions:
(1) Over the past two weeks, how often did you listen to one of the audio materials? Never Less than half the days More than half the days Once each day More than once per day
(2a) During your most recent chemotherapy session, did you listen to any of the audio materials? Yes; No (2b) If no, please explain why _______________
(3) In a general sense, how satisfied are you with the audio materials you have received? Very satisfied 5; Mostly satisfied 4; Indifferent 3; or mostly dissatisfied 2; Very dissatisfied 1
At the end of the prehabilitation sessions, patients will fill in an 'acceptability of psychotherapy' evaluation (CSQ scale).
Smoking cessation: If required. Sunnybrook has a comprehensive smoking cessation program in place. 16% of patients in the Odette Cancer Program are smokers (internal data). For those patients who identify as a smoker (answered "yes" to the question of "Have you used any forms of tobacco in the past 6 months?"), a brief smoking cessation intervention will be provided outlining the benefits of quitting as well as the impact of continued smoking on the treatments for cancer (chemotherapy, surgery and radiation). These patients will be given education on the use of nicotine replacement therapy and will be offered a redemption card for 4 boxes of free nicotine replacement therapy products of their choice and advised to speak with their pharmacist. Patients will also be encouraged to accept a referral to Smokers Helpline which provides free smoking cessation counseling (telephone, texting or web-based) with a Quit Coach.
- Being tested
- Prehabilitation
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PrehabilitationCombination product
stress counseling, exercise, nutritional counseling, smoking cessation counseling
| Study group | Role | What they receive |
|---|---|---|
| Standard of Care | No intervention | Patients will receive standard treatment without added intervention. |
| Intervention | Experimental | These patients will receive standard treatment plus multimodal intervention (prehabilitation program) including :
exercise, nutritional counseling, stress counseling, smoking cessation) before starting chemotherapy. Receives: Combination Product: Prehabilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recruitment rate (percent reported by the research analyst )
What percent of eligible patients were successfuly recruitted in the study
Measured: 18 month
Exercise compliance rate (percent reported by analysis of data)
number of exercise sessions per week and mean compliance rate (percent of the prescribed exercises within sessions)
Measured: 18 month
Attrition rate (percent reported by data analysis)
what percent of the patients left the study?
Measured: 18 month
Stress consultation compliance rate (percent reported by data analyst)
Percent of the patients that have satisfaction with counseling and use of education meterials that are provided to them.
Measured: 18 months
Secondary outcomes (5)
Quality of life (FACT-B questionnair)
The Functional Assessment of Cancer Therapy - Breast (FACT-B) is a validated quality of life scale for breast cancer survivors capturing subdomains of physical, social, emotional, and functional well-being as well as specific concerns for breast cancer. The FACT-An, a validated fatigue scale for cancer survivors, the PROMIS which looks at cognitive functioning will be used.
Measured: 18 months
Physical activity volume
How much activity the patients complete on a weekly basis
Measured: 6 months
Aerobic fitness (6 minute walk test)
How does 6 min walk test change after intervention and treatment in both arms.
Measured: 6 months
Arm fitness (grip strength test)
Grip strength will be assessed and compared
Measured: 6 months
Exercise tolerance ( FACT-An questionnair)
how the patients tolerate to the exercise program
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jun 2018
- Study start18 Jul 2018
- Primary completion31 Mar 2023
- Study completion31 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Sunnybrook Health Sciences CentreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- 2 arms: Intervention and Control (chosen by closed envelope, 1:1 randomization)
- Masking
- None (open label)
- Enrolment
- 63 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Sponsor type
- University, hospital or other
- Collaborators
- University Health Network, Toronto
- Responsible party
- Principal investigator, Frances Wright, Sunnybrook Health Sciences Centre
- Investigators
- Frances Wright, MD, Principal investigator, Sunnybrook Health Sciences Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03564171
- Sponsor's protocol ID
- 041-2018
- Status last verified
- Apr 2023
- First submitted
- 18 Mar 2018
- Last updated
- 12 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Feasibility Study Comparing a Multimodal Prehabilitation Protocol to Normal Care for Women Undergoing Neo-adjuvant Chemotherapy for Breast Cancer
- ClinicalTrials.gov ID
- NCT03564171
- Acronym / sponsor ID
- 041-2018
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 63 participants (actual)
- Lead sponsor
- Sunnybrook Health Sciences CentreUniversity, hospital or other
- Collaborators
- University Health Network, Toronto
- Study start
- 18 Jul 2018 (actual)
- Primary completion
- 31 Mar 2023 (actual)
- Study completion
- 31 Mar 2023 (actual)
- First posted
- 20 Jun 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess recruitment rate, attrition, compliance with weekly exercise, smoking cessation, and quality of life with a multimodal prehabilitation protocol for women with breast cancer undergoing neo-adjuvant chemotherapy for breast cancer.
Detailed description
Proposal: A randomized controlled feasibility study comparing a multi-modal prehabilitation protocol to usual care for women undergoing neo-adjuvant therapy for breast cancer.
Methods: Study population: Sixty patients who are undergoing curative intent neo-adjuvant chemotherapy for breast cancer will be randomized to intervention (n=30) or standard care (n=30) at a single site (Sunnybrook).
Intervention: A multi-modal program composed of an exercise prescription that will progressively increase in intensity and duration towards the current physical activity guidelines, nutritional counseling, stress counseling, and smoking cessation (as needed).
Intervention: Exercises will be instructed and demonstrated by a physiotherapist prior to the initiation of chemotherapy and will continue up until surgery. Nutritional and stress counseling, as well as smoking cessation, will be offered at initial consult with physiotherapist.
Exercise Protocol: The prehabilitation program entails a home-based exercise with both total-body physical exercise and exercises specific to the upper quadrant over the period between baseline assessment and surgery. The exercise prescription will be provided by a physiotherapist based upon the baseline assessment and will consist of a goal of 60 minutes of home-based, unsupervised exercise on 4 days per week, including aerobic and resistance training. Each session will be individualized and based upon the baseline assessment and generally include: a 5-minute warm-up, 25 minutes of moderate intensity aerobic exercise (for example: brisk walking, treadmill, stationary bike) (intensity of 3-6 on the 0-10 Rating of Perceived Exertion Scale) (attached, Appendix A) and 25 minutes of upper quadrant-specific training (Appendix B), and a 5-minute cool-down consisting of stretches (Appendix B). The program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. The participant will have an opportunity to try the exercises in the presence of the physiotherapist who will provide corrective feedback if necessary. The physiotherapist will discuss safety precautions (posture, breathing, etc.) and provide the participant with an exercise manual that describes the exercises in the program and the safety precautions. To complete the exercises at home, each participant will be provided with resistance Theraband(s) (red and yellow) required to complete the upper quadrant exercises that they may keep at the end of the study. Training intensity progression will occur when the participant can complete the aerobic exercise with mild exertion and/or when the participant can complete 15 repetitions of a given upper quadrant exercise without eliciting at least moderate exertion (i.e. 3 to 6 on the Rating of Perceived Exertion scale). The prehabilitation program will be supported with a manual including institutionally created postoperative rehabilitation exercises that comprise a significant proportion of the preoperative exercise prescription. The physiotherapist will communicate with the participants every 2 weeks to ensure program compliance, support appropriate progression, and to address any barriers to exercise (including questions about appropriate exercise completion) that may prevent ongoing participation (see contact with team Table 1).
Grip Strength: Grip strength is commonly used to assess upper extremity strength in patients with breast cancer (Sagen 2009) and will be assessed via the "Jamar Hand" dynamometer according to established protocols.
Aerobic Fitness: Aerobic fitness will be measured using the 6-minute walk test (6 Minute Walk Test). This test is a practical standardized measure of functional capacity and has been widely used for measuring the submaximal level of functional capacity in cancer patients (Vardar 2015, Santa Mina 2014, Schmidt 2013). This test will measure the distance that the patient can walk on a flat, hard surface in a period of 6 minutes.
Nutrition counseling: The registered dietitian will provide an initial individualized nutrition assessment and counseling session. The consultation will be about 60 minutes in length and can be conducted in person or via telephone.
The patient's nutritional history, assessment of usual intake and weight history will be reviewed to help identify any nutritional issues/concerns. The session will focus on the goals of nutrition before and during treatment, provide strategies to help the patient optimize or enhance the nutritional quality of the diet, maintain a healthy weight and minimize weight gain and address any nutrition-related questions or concerns.
The registered dietitian will follow-up with the patient 4 weeks after the initial consultation to review the nutrition care goals and outcomes, answer questions re. any potential nutrition-related side effects from treatment and address any other questions or concerns.
The patient will be encouraged to contact the dietitian as needed during treatment for on-going support of if any nutrition related questions or concerns.
Stress counseling: Stress management intervention: Stress management intervention will consist of a 60-90 minute individual session with a psychiatrist specializing in psychosocial oncology. The therapy session will be cognitive-behavioral in orientation. The components will include a psychoeducational module on the stress response to physical symptoms; problem-solving and coping skills; relaxation techniques; and guided imagery. During the initial session, participants will be oriented conceptually to four types of interventions for reducing anxiety and coping with stress: (1) Progressive muscle relaxation; (2) mindfulness; (3) deep breathing; and (4) imagery/visualization. Each intervention will have accompanying written materials, which will also contain links to online audio materials. The additional materials contain written and spoken instructions allowing for self-directed learning and practice of each of the four stress-reducing interventions. Participants will be invited to choose one or two of the four strategies to practice with the therapist in the initial session, and in any subsequent sessions that participants attend. The therapist will instruct participants to choose one audio file to listen to at each chemotherapy session.
Optional face-to-face 60 minute individual booster sessions will be offered to participants on a monthly basis until surgery, in order to review problem solving and coping skills, relaxation techniques, and guided imagery. If patients are found to need a greater frequency of psychiatric intervention or undergo a psychiatric crisis, or if they require psychotropic medications at any point during the study, the PI will be informed and a referral will be made to an alternate psychiatrist (if the patient chooses) at the Odette Cancer Centre who is not involved in this study.
Every 2 weeks the patients in the intervention (prehabilitation arm) will be asked these questions:
At each telephone follow-up or email, the frequency of use and acceptability will be assessed with the following questions:
(1) Over the past two weeks, how often did you listen to one of the audio materials? Never Less than half the days More than half the days Once each day More than once per day
(2a) During your most recent chemotherapy session, did you listen to any of the audio materials? Yes; No (2b) If no, please explain why _______________
(3) In a general sense, how satisfied are you with the audio materials you have received? Very satisfied 5; Mostly satisfied 4; Indifferent 3; or mostly dissatisfied 2; Very dissatisfied 1
At the end of the prehabilitation sessions, patients will fill in an 'acceptability of psychotherapy' evaluation (CSQ scale).
Smoking cessation: If required. Sunnybrook has a comprehensive smoking cessation program in place. 16% of patients in the Odette Cancer Program are smokers (internal data). For those patients who identify as a smoker (answered "yes" to the question of "Have you used any forms of tobacco in the past 6 months?"), a brief smoking cessation intervention will be provided outlining the benefits of quitting as well as the impact of continued smoking on the treatments for cancer (chemotherapy, surgery and radiation). These patients will be given education on the use of nicotine replacement therapy and will be offered a redemption card for 4 boxes of free nicotine replacement therapy products of their choice and advised to speak with their pharmacist. Patients will also be encouraged to accept a referral to Smokers Helpline which provides free smoking cessation counseling (telephone, texting or web-based) with a Quit Coach.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- 2 arms: Intervention and Control (chosen by closed envelope, 1:1 randomization)
| Arm | Type | Receives |
|---|---|---|
| Standard of Care | No intervention | –Patients will receive standard treatment without added intervention. |
| Intervention | Experimental | Combination Product: PrehabilitationThese patients will receive standard treatment plus multimodal intervention (prehabilitation program) including : exercise, nutritional counseling, stress counseling, smoking cessation) before starting chemotherapy. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- 18 years and older, able to give consent, ECOG 0-1
Key exclusion criteria (1 listed)
- pregnant, > 80 years, medical contraindications to exercise. History of severe and persistent mental illness, cognitive impairment, recent suicide attempts or >11 on "Hospital Anxiety and Depression Scale". If very active (> 24) on the Godin-Shephard scale.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prehabilitationstress counseling, exercise, nutritional counseling, smoking cessation counseling | Combination product | Intervention |
Primary outcome
Recruitment rate (percent reported by the research analyst )
Time frame: 18 month
What percent of eligible patients were successfuly recruitted in the study
Exercise compliance rate (percent reported by analysis of data)
Time frame: 18 month
number of exercise sessions per week and mean compliance rate (percent of the prescribed exercises within sessions)
Attrition rate (percent reported by data analysis)
Time frame: 18 month
what percent of the patients left the study?
Stress consultation compliance rate (percent reported by data analyst)
Time frame: 18 months
Percent of the patients that have satisfaction with counseling and use of education meterials that are provided to them.
5 secondary outcomes
Quality of life (FACT-B questionnair)
Time frame: 18 months
Physical activity volume
Time frame: 6 months
Aerobic fitness (6 minute walk test)
Time frame: 6 months
Arm fitness (grip strength test)
Time frame: 6 months
Exercise tolerance ( FACT-An questionnair)
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Apr 2023.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Frances Wright, MD principal investigator
Sunnybrook Health Sciences Centre
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Prehabilitation in people with Breast Cancer and Rehabilitation, run by Sunnybrook Health Sciences Centre at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recruitment rate (percent reported by the research analyst ) (time frame: 18 month). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Apr 2023.